Page 166 - Read Online

Page 6 of 6 Carvalho et al. Hepatoma Res 2018;4:15 I http://dx.doi.org/10.20517/2394-5079.2018.13

9. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J
Hepatol 2008;48:335-52.
10. Bonilla Guerrero R, Roberts LR. The role of hepatitis B virus integrations in the pathogenesis of human hepatocellular carcinoma. J Hepatol
2005;42(5):760-77.
11. Albeldawi M, Soliman M, Lopez R, Zein NN. Hepatitis C virus associated primary hepatocellular carcinoma in non-cirrhotic patients. Dig
Dis Sci 2012;57:3265-70.
12. Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Srishord M. Changes in the prevalence of the most common causes of chronic
liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 2011;9:524-30.
13. Welzel TM, Graubard BI, Zeuzem S, El-Serag HB, Davila JA, McGlynn KA. Metabolic syndrome increases the risk of primary liver cancer
in the United States: a study in the SEER-Medicare database. Hepatology 2011;54:463-71.
14. European Association for the Study of the Liver; European Organization for Research and treatment of Cancer. EASL-EORTC clinical
practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908-43.
15. International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the
international consensus group for hepatocellular neoplasia. Hepatology 2009;49:658-64.
16. Llovet JM, Burroughs A, Bruix J. Hepatocellularcarcinoma. Lancet 2003;362:1907-17.
17. Pereira LM, Martelli CM, Moreira RC, Merchan-Hamman E, Stein AT, Cardoso MR, Figueiredo GM, Montarroyos UR, Braga C, Turchi
MD, Coral G, Crespo D, Lima ML, Alencar LC, Costa M, Dos Santos AA, Ximenes RA. Prevalence and risk factors of hepatitis C
infectious in Brazil. 2005 through 2009: a cross-sectonal study. BMC Infect Dis 2013;13:60.
18. Farazi PA, Depinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006;6:674-87.
19. Adams LA, Lymp JF, Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of nonalcoholic fatty liver disease: a
population-based cohort study. Gastroenterology 2005;129:113-21.
20. Ekstedt M, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S. Long-term follow-up of patients with NAFLD
and elevated liver enzymes. Hepatology 2006;44:865-73.
21. Dam-Larsen S, Franzmann M, Andersen IB, Christoffersen P, Jensen LB, Sørensen TI, Becker U, Bendtsen F. Long term prognosis of fatty
liver: risk of chronic liver disease and death. Gut 2004;53:750-5.
22. Rosmorduc O, Fartoux L. HCC and NASH: how strong is the clinical demonstration? Clin Res Hepatol Gastroenterol 2012;36:202-8.
23. Cotrim HP, Oliveira CP, Coelho HS, Alvares-da-Silva MR, Nabuco L, Parise ER, Ivantes C, Martinelli AL, Galizzi-Fiho J, Carriho FJ.
Members of the Brazilian society of hepatology HCC. Clinics (Sao Paulo) 2016;71:281-4.
24. Alkofer B, Lepennec V, Chiche L. Hepatocellular cancer in the non-cirrhotic liver. J Visc Surg 2011;148:3-11.
25. Sarpel U, Ayo D, Lobach I, Xu R, Newman E. Inverse relationship between cirrhosis and massive tumours in hepatocellular carcinoma.
HPB (Oxford) 2012;14:741-5.